05.06 15:02 | dpa-AFX: *ABBVIE SAYS FIRST PATIENT TREATED WITH INVESTIGATIONAL ABBV-383 IN CERVINO PHASE 3 STUDY |
05.06 06:32 | dpa-AFX: *HSBC HEBT ABBVIE AUF 'BUY' - ZIEL 185 USD |
05.06 06:32 | dpa-AFX: *HSBC RAISES ABBVIE TO 'BUY' - PRICE TARGET 185 USD |
04.06 15:00 | dpa-AFX: AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients |
04.06 14:42 | dpa-AFX: *ABBV : RINVOQ AVAILABLE FOR PEDIATRIC PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS &PSORIATIC ARTHRITIS |
31.05 08:45 | dpa-AFX: AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis |
31.05 08:24 | dpa-AFX: *ABBVIE'S RISANKIZUMAB RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS |
28.05 14:04 | dpa-AFX: *ABBVIE SHOWCASES ROBUST SOLID TUMOR PIPELINE AT ASCO 2024, WITH NEW DATA FROM ADC PLATFORM |
23.05 22:06 | dpa-AFX: *ABBVIE COMPLETES ACQUISITION OF LANDOS BIOPHARMA |
13.05 15:17 | dpa-AFX: AbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric Therapies |
13.05 14:44 | dpa-AFX: *ABBVIE TO PAY GILGAMESH $65 MLN UPFRONT FOR PSYCHIATRIC THERAPIES, POTENTIAL $1.95 BLN IN OPTION FEES, AND OTHERS |
13.05 14:42 | dpa-AFX: *ABBVIE, GILGAMESH COLLABORATE TO DEVELOP NEXT-GENERATION THERAPIES FOR PSYCHIATRIC DISORDERS |
08.05 15:37 | dpa-AFX: AbbVie's Qulipta Gets Health Canada Approval For Chronic Migraine In Adults |
08.05 14:04 | dpa-AFX: *ABBVIE : HEALTH CANADA APPROVES QULIPTA FOR PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN ADULTS |
30.04 12:47 | dpa-AFX: *DZ BANK SENKT FAIREN WERT FÜR ABBVIE AUF 188 (196) USD - 'KAUFEN' |
30.04 12:47 | dpa-AFX: *DZ BANK CUTS FAIR VALUE FOR ABBVIE TO 188 (196) USD - 'BUY' |
26.04 15:07 | MÄRKTE USA/Wall Street mit günstigen Preisdaten freundlich gesehen |
26.04 14:07 | dpa-AFX: ROUNDUP: AbbVie Lifts FY24 Outlook After Higher Q1 Results |
26.04 13:45 | dpa-AFX: AbbVie Q1 Profit Increases, beats estimates |
26.04 13:38 | dpa-AFX: *ABBVIE Q1 NET EARNINGS ATTRIBUTABLE TO ABBVIE $1.369 BLN VS $239 MLN LAST YEAR |
|